| Gene name: | MIR1827 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | -- |
| Cell name: | HCT116,RKO |
| Gene ID: | 100302217 |
| Category: | ncRNA |
| Phenotype: | Colorectal cancer |
| Experimental category: | HL |
| PMID: | 26840028 |
| Experiment: | Knockdown//SA-β-gal activity assay |
| Description: | MiR-1827 enhanced p53-mediated senescence in HCT116 cells treated with Doxorubicin.MiR-1827 enhanced p53-mediated senescence in RKO cells treated with Doxorubicin. miR-1827 inhibitor reduced p53-mediated senescence in HCT116 cells treated with Doxorubicin.Compared with control inhibitor, miR-1827 inhibitor significantly inhibited Doxorubicin-induced senescence in HCT116 p53+/+ cells but not in HCT116 p53–/–cells. |
| Target gene: | MDM2//P53 |
| Official symbol(s): | MDM2//P53 |
| R-AG-Target gene: | Downregulation//Upregulation |
| Subcategory: | Unclear |
| Target gene experiment: | Western blot |
| Target gene description: | miR-1827 reduced MDM2 protein levels and increased p53 protein levels in HCT116 cells treated with Doxorubicin (Dox). |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...